Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results

Overview

Journal Infect Control Hosp Epidemiol

Publisher Cambridge University Press

Specialties Health Services
Infectious Diseases
Nursing
Public Health

Date 2009 Feb 25

PMID 19236281

Citations 12

Authors

Nira R Pollock

Suely S Kashino

Danielle R Napolitano

Alex Sloutsky

Swati Joshi

Jasmine Guillet

Michael Wong

Edward Nardell

Antonio Campos-Neto

Affiliations

Soon will be listed here.

Abstract

To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.

Citing Articles

Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.

Sodre-Alves B, Toledo M, Zimmermann I, de Araujo W, Tavares N Rev Soc Bras Med Trop. 2024; 57:e004022024.

PMID: 38536998 PMC: 10962359. DOI: 10.1590/0037-8682-0504-2023.

A differential DNA methylome signature of pulmonary immune cells from individuals converting to latent tuberculosis infection.

Karlsson L, Das J, Nilsson M, Tyren A, Pehrson I, Idh N Sci Rep. 2021; 11(1):19418.

PMID: 34593857 PMC: 8484443. DOI: 10.1038/s41598-021-98542-3.

Detection of complex DNA in CD34-positive peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study.

Belay M, Tulu B, Younis S, Jolliffe D, Tayachew D, Manwandu H Lancet Microbe. 2021; 2(6):e267-e275.

PMID: 34100007 PMC: 8172384. DOI: 10.1016/S2666-5247(21)00043-4.

Factoring Prior Treatment into Tuberculosis Infection Prevalence Estimates, United States, 2011-2012.

Vonnahme L, Haddad M, Navin T Emerg Infect Dis. 2019; 25(10):1949-1951.

PMID: 31538921 PMC: 6759264. DOI: 10.3201/eid2510.190439.

Sub-clinical abnormalities detected by PET/MRI in household tuberculosis contacts.

Molton J, Thomas B, Pang Y, Khor L, Hallinan J, Naftalin C BMC Infect Dis. 2019; 19(1):83.

PMID: 30678651 PMC: 6346497. DOI: 10.1186/s12879-019-3705-0.

References

Wilkinson K, Kon O, Newton S, Meintjes G, Davidson R, Pasvol G . Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis. 2006; 193(3):354-9. DOI: 10.1086/499311. View

Mazurek G, Jereb J, LoBue P, Iademarco M, Metchock B, Vernon A . Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005; 54(RR-15):49-55. View

Goletti D, Parracino M, Butera O, Bizzoni F, Casetti R, Dainotto D . Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res. 2007; 8:5. PMC: 1794408. DOI: 10.1186/1465-9921-8-5. View

Chee C, Khinmar K, Gan S, M S Barkham T, Pushparani M, Wang Y . Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med. 2006; 175(3):282-7. DOI: 10.1164/rccm.200608-1109OC. View

Ewer K, Millington K, Deeks J, Alvarez L, Bryant G, Lalvani A . Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006; 174(7):831-9. DOI: 10.1164/rccm.200511-1783OC. View